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Polymerase chain reaction–based replicon typing rep-
resents a novel method to describe the dissemination and
follow the evolution of resistance plasmids. We used this
approach to study 26 epidemiologically unrelated
Enterobacteriaceae and demonstrate the dominance of
incompatibility (Inc) A/C or Inc N-related plasmids carrying
some emerging resistance determinants to extended-spec-
trum cephalosporins and carbapenems.
U
nderstanding the molecular epidemiology of resist-
ance plasmids has been a major issue since scientists
became aware of plasmids’role in the spread of antimicro-
bial drug resistance. However, understanding this epidemi-
ology has been complex because of the diversity and
promiscuity of these elements. The plasmid replication
system, which dictates the plasmid’s behavior (host range,
copy number) is the major plasmid landmark from a bio-
logic standpoint; it is used for plasmid classification and
identification (1). Plasmids were originally classified in
incompatibility (Inc) groups (2). Inc is a manifestation of
plasmid relatedness based on commonality of replication
controls. The standard procedure for determining Inc
groups requires laborious hands-on work, multiple conju-
gation, transformation assays, or hybridization experi-
ments (1–3).
Our objective of understanding the relationship among
resistance plasmids prompted us to develop a polymerase
chain reaction (PCR)–based replicon typing method (4).
Our study has 2 aims: 1) to investigate phylogenetic relat-
edness among plasmids carrying extended-spectrum
cephalosporin (ESC) and carbapenem resistance determi-
nants emerging in 3 different countries (Greece, Italy, and
the United States) and 2) to ascertain the sensitivity of the
method.
The Study
PCR-based replicon typing was applied to type the
resistance plasmids carried by 26 Escherichia coli
transconjugants or transformants obtained from epidemio-
logically unrelated clinical isolates of Enterobacteriaceae
associated with community- or hospital-acquired infec-
tions in the United States or southern Europe (Italy and
Greece). The resistance plasmids carried genes encoding
β-lactamases of Ambler class A (SHV-12), B (VIM-1 or
VIM-4), and C (CMY-2, CMY-4, or CMY-13) (Table),
which represent key emerging resistance determinants to
ESC and carbapenems.
Eighteen primer pairs were used to perform 5 multiplex
and 3 simplex PCRs, which recognized FIA, FIB, FIC,
HI1, HI2, I1-Iγ, L/M, N, P, W, T, A/C, K, B/O, X, Y, and
FII replicons (4). All amplified replicons were sequenced
by standard procedures and used as specific probes to con-
firm the replicon typing results by Southern blot hybridiza-
tion on purified plasmid DNA (data not shown).
The plasmid donors from the United States consisted of
4 previously characterized ESC-resistant Salmonella iso-
lates submitted to the National Antimicrobial Resistance
Monitoring System (NARMS) from 1996 to 1998 (12) and
6 ESC-resistant Escherichia coli O157:H7 isolates collect-
ed by NARMS from 2000 to 2001 (5). During the study
periods, participating state and local public health labora-
tories forwarded every tenth non-Typhi type Salmonella
and every fifth E. coli O157 isolate they received to the
Centers for Disease Control and Prevention for suscepti-
bility testing. This collection includes representatives from
sporadic and outbreak infections (5,12). The 6 Salmonella
and 4 E. coli plasmid donors selected for this study were a
small sample of epidemiologically unrelated isolates rep-
resentative of those carrying a blaCMY-2 β-lactamase gene
on plasmids classified as type A or B on the basis of the
blaCMY-2 hybridization pattern (6,13). The PCR-based
replicon typing method assigned the A/C and I1 replicons
to type Aand type B plasmids, respectively (Table), which
was confirmed by DNAsequencing. The I1-type amplicon
sequences were identical to the R64 IncI1 reference plas-
mid (no. AP005147), whereas the A/C-type amplicon
sequences exhibited 26 nucleotide (nt) substitutions with
respect to the RA1 IncA/C reference plasmid (no.
X73674), which caused 3 amino acid variations.
Therefore, the A/C-replicon from the US plasmids may
represent a new replicon variant, which we designated
repA/C2 (DNA sequence released under EMBL accession
no. AM087198). The Figure shows conserved PstI restric-
tion profiles obtained for the A/C2 plasmids that are differ-
ent from those exhibited by the I1 plasmids.
The plasmid donors from Italy consisted of 7 mul-
tidrug-resistant isolates of various species of
Enterobacteriaceae carrying either blaSHV-12 or  blaCMY-4
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These isolates had been collected from 2002 to 2003 at 4
different hospitals in northern or central Italy (7,8) and
were epidemiologically unrelated, except for IT-VA416/02
and IT-VA417/02, which were from the same patient (7).
PCR replicon typing of the 5 blaSHV-12–carrying plasmids
detected 3 repFII (100% identical to the reference
sequence no. M33752), 1 repI1 (100% identical to the R64
plasmid), and 1 repA/C1 (99% homologous to the RA1
plasmid) (Table), suggesting mobilization of this gene
among different plasmid scaffolds. The blaSHV-12 plasmids
showed different PstI restriction patterns, which confirmed
their diversity (Figure). The 2 plasmids carrying blaVIM-4
and blaCMY-4 were assigned by PCR replicon typing to the
A/C type. The sequence of these replicons showed the
same 26 characteristic nucleotide substitutions of the A/C2-
replicon identified in the US plasmids. These 2 A/C2-plas-
mids showed an apparently identical PstI restriction
profile (data not shown), which was also very similar to
that of some USA blaCMY-2 plasmids (see the 2039 and
3977 US plasmids and the Italian VA416/02 plasmid in the
Figure). The 2 Italian A/C2 plasmids, in addition to blaCMY-
4 (which is a blaCMY-2 variant different by only a single
nucleotide substitution), also carried the blaVIM-4 carbapen-
emase gene, which has not been reported on blaCMY-2–car-
rying plasmids from the United States and may represent a
novel acquisition. These findings indicate intercontinental
spread of these plasmids and novel acquisition of resist-
ance genes.
The plasmid donors from Greece consisted of a collec-
tion of 7 Klebsiella pneumoniae isolates carrying the
blaVIM-1 gene (9) and 2 E. coli isolates carrying blaVIM-1
and blaCMY-13 genes (10). These isolates, randomly collect-
ed from 5 different hospitals in Athens and Piraeus from
2001 to 2003, are representative of the VIM-1–producing
isolates circulating in Greece. No repetitive samples were
taken from patients. All isolates exhibited decreased sus-
ceptibility to carbapenems. Restriction analysis of these
plasmids classified them into 6 different groups on the
basis of their restriction profiles (Figure). By replicon typ-
ing, all of these plasmids were assigned to the same repN-
type replicon, which exhibited 2-nt point mutations (99%
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(no. NC_003292), an indication that they were phyloge-
netically related and probably evolved from a common
ancestor. Although one might expect similar plasmid scaf-
folds to exist among isolates in Greece and Italy because
of geographic proximity, this was not the case. This find-
ing explains the great variability of resistance plasmids
carrying different combinations of resistance genes.
Since the origin of replication is a constant and con-
served part of a plasmid, replicon typing focused on this
portion of the plasmid is a more sensitive and specific
method for identifying phylogenetically related plasmids
than restriction-based analysis of the entire plasmid. This
fact is probably due to the presence of multiple mobile ele-
ments (IS elements, transposons, integrons) that can medi-
ate rearrangements of the plasmid scaffolds, which leads to
the formation of apparently divergent plasmids. In fact,
this phenomenon was demonstrated for the GR-541 plas-
mid that contains multiple copies of insertion sequences
and other mobile genetic elements within its scaffold (14).
Conclusions
APCR-based replicon typing approach was successful-
ly applied to relevant resistance plasmids. Coupled with
sequencing, the approach allowed high-resolution typing
of the plasmid replicons. Typing results provided original
insights into the molecular epidemiology of resistance
plasmids. For instance, the blaCMY-2–carrying plasmid cir-
culating in the United States was also detected in Europe
in the form of a derivative that also carries the VIM-4 car-
bapenemase determinant. This finding demonstrates that
plasmids carrying resistance to clinically relevant antimi-
crobial agents can spread worldwide among bacteria
responsible for both nosocomial and community-acquired
infections. The heterogeneity among Italian plasmids
encoding SHV-12 (the most prevalent SHV-type extended-
spectrum  β-lactamase in this country) (15) suggests a
notable potential for this determinant to spread among dif-
ferent plasmid replicons. On the other hand, replicon typ-
ing indicated that the VIM-1–encoding plasmids from
Greece were all related despite their different restriction
profiles, which points out the common origin of these plas-
mids. The blaCMY-13 gene from Greece is located on the
repN plasmid, whereas Italy and the United States share
the A/C2 plasmid as a vehicle of the blaCMY gene, despite
their geographic distance. Further research is necessary to
determine the influences on plasmid trafficking as well as
further similarities and differences. Replicon identification
may provide useful clues to the evolution of these resistant
plasmids. The ability to trace and screen plasmids by PCR
may facilitate further understanding of the horizontal
transfer of antimicrobial drug resistance.
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Figure. Restriction enzyme analysis of
plasmid analyzed in this study. Numbers
and letters above each lane indicate strain
reference names as defined in the Table. M
is the1-kb Plus DNA ladder (Gibco-BRL,
Gaithersburg, MD, USA). Plasmids were
transferred by conjugation or transforma-
tion in Escherichia coli K12 strains and puri-
fied by Midi-prep purification kit. Plasmids
were digested with restriction endonucle-
ase  PstI and separated by agarose (1%)
gel electrophoresis in 1× TBE buffer. DNA
was stained with ethidium bromide and
visualized under UV light. The replicons
and the β-lactamase genes carried by each
group of plasmids are indicated below the
figure.5. Whichard JM, Joyce K, Fey P, Nelson JM, Angulo FJ, Barrett TJ. β-
lactam resistance and Enterobacteriaceae, United States. Emerg
Infect Dis. 2005;11:1464–6.
6. Carattoli A, Tosini F, Giles WP, Rupp ME, Hinrichs SH, Angulo FJ,
et al. Characterization of plasmids carrying CMY-2 from expanded-
spectrum cephalosporin-resistant Salmonella isolated in the United
States between 1996 and 1998. Antimicrob Agents Chemother.
2002;46:1269–72.
7.  Luzzaro F, Docquier JD, Colinon C, Endimiani A, Lombardi G,
Amicosante G, et al. Emergence in Klebsiella pneumoniae and
Enterobacter cloacae clinical isolates of the VIM-4 metallo-β-lacta-
mase encoded by a conjugative plasmid. Antimicrob Agents
Chemother. 2004;48:648–50.
8.  Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S,
Amicosante G, et al. Trends in the production of extended-spectrum
β-lactamases among enterobacteria of medical interest. Report of the
second Italian nationwide survey. J Clin Microbiol. 2006; 44:
1659–64.
9. Giakkoupi P, Xanthaki A, Kanelopoulou M, Vlahaki A, Miriagou V,
Kontou S, et al. VIM-1 metallo-β-lactamase-producing  Klebsiella
pneumoniae strains in Greek Hospitals. J Clin Microbiol.
2003;41:3893–6. 
10. Miriagou V, Tzelepi E, Gianneli D, Tzouvelekis LS. Escherichia coli
with a self-transferable, multi-resistant plasmid coding for the metal-
lo-β-lactamase VIM-1. Antimicrob Agents Chemother. 2003;
47:395–7.
11. Clinical and Laboratory Standards Institute. Performance standards
for antimicrobial disk susceptibility tests; approved standard. 9th ed.
Wayne (PA): The Institute; 2006.
12. Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, et
al. Emergence of domestically acquired ceftriaxone-resistant
Salmonella infections associated with AmpC beta-lactamase. JAMA.
2000;284:3151–6.
13. Giles WP, Benson AK, Olson ME, Hutkins RW, Whichard JM,
Winokur PL, et al. DNA sequence analysis of regions surrounding
blaCMY-2 from multiple Salmonella plasmid backbones. Antimicrob
Agents Chemother. 2004;48:2845–52.
14. Miriagou V, Carattoli A, Tzelepi E, Villa L, Tzouvelekis LS. IS26-
associated In4-type integrons forming multiresistance loci in enter-
obacterial plasmids. Antimicrob Agents Chemother. 2005;49:3541–3.
15. Perilli M, Dell’Amico E, Segatore B, De Massis MR, Bianchi C,
Luzzaro F, et al. Molecular characterization of extended-spectrum β-
lactamases produced by nosocomial isolates of Enterobacteriaceae
from an Italian nationwide survey. J Clin Microbiol. 2002;40:611–4.
Address for correspondence: Alessandra Carattoli, Department of
Infectious, Parasitic, Immune-mediated Diseases, Istituto Superiore di
Sanità, Rome, Viale Regina Elena 299, 00161 Rome, Italy; email:
alecara@iss.it
DISPATCHES
1148 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 7, July 2006
Search
past issues